Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer

Chiara Nicolazzo; Flavia Loreni; Salvatore Caponnetto; Valentina Magri; Anna Rita Vestri; Rita Zamarchi; Angela Gradilone; Antonella Facchinetti; Elisabetta Rossi; Enrico Cortesi; Paola Gazzaniga

doi:10.18632/oncotarget.27794

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer

Chiara Nicolazzo _, Flavia Loreni, Salvatore Caponnetto, Valentina Magri, Anna Rita Vestri, Rita Zamarchi, Angela Gradilone, Antonella Facchinetti, Elisabetta Rossi, Enrico Cortesi and Paola Gazzaniga

PDF | Full Text | Supplementary Files | How to cite

Oncotarget. 2020; 11:4115-4122. https://doi.org/10.18632/oncotarget.27794

Metrics: PDF 1033 views | Full Text 1536 views | ?

Abstract

Chiara Nicolazzo1, Flavia Loreni1, Salvatore Caponnetto2, Valentina Magri2, Anna Rita Vestri3, Rita Zamarchi4, Angela Gradilone1, Antonella Facchinetti4^,5, Elisabetta Rossi4^,5, Enrico Cortesi2 and Paola Gazzaniga1

1 Department of Molecular Medicine, Liquid Biopsy Unit, Sapienza University of Rome, Rome, Italy

2 Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy

3 Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy

4 Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

5 Department of Surgery, Oncology and Gastroenterology, University of Padova, Italy

Correspondence to:

Chiara Nicolazzo,

email:

[email protected]

Keywords: cancer stem cells; CD44v6; circulating tumor cells; colorectal cancer; CellSearch^®

Received: July 22, 2020 Accepted: October 17, 2020 Published: November 10, 2020

Copyright: © 2020 Nicolazzo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

CD44v6, the CD44 isoform mostly involved in cancer cell migration and invasion, has been identified as a functional biomarker and therapeutic target in colon cancer stem cells. We here provide evidence that baseline CD44v6-positive CTC predict treatment failure in patients with metastatic colorectal cancer undergoing first-line chemotherapy. We suggest that CD44v6-positive CTC can be used to early detect intrinsic drug resistance in this cancer type.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27794

Publication Alerts

Research Papers:

Baseline CD44v6-positive circulating tumor cells to predict first-line treatment failure in patients with metastatic colorectal cancer

Abstract